Diaglu Mechanism of Action

Pharmacology: Diaglu is hypoglycaemic sulfonylurea which stimulates insulin secretion by the pancreas. Its action on insulin secretion is mainly due to the restoration of the early phase, resulting in physiological release of insulin. In addition to this pancreatic action, it has been demonstrated that Diaglu administration improves the metabolic utilization of glucose at a peripheral level. The extrapancreatic action is not due to a modification in the number of insulin receptors, but may be due to the potentiation of the post-receptor pathways. Thus, Diaglu restores glycaemic control throughout 24 hrs. It normalizes fasting and postprandial blood sugar.
In man, apart from having hypoglycaemic effect, Diaglu has been shown to reduce platelet hyperadhesiveness and hyperaggregation, and to increase fibrinolytic activity. These factors are thought to be implicated in the pathogenesis of the long-term complications of diabetes mellitus.
Controlled studies in patients with diabetic retinopathy suggest that these effects of Diaglu are beneficial in slowing down the progression of retinopathy.